Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MarketBeat

Allstate’s Comeback Is Turning Into a Profit Machine

Allstate profits have surged as underwriting, premiums, and investment income improve, but severe weather remains a key risk for investors.

Gamehaus Q3 Earnings Call Highlights

Gamehaus (NASDAQ:GMHS) reported third-quarter fiscal 2026 revenue above its prior guidance range while management emphasized improving profitability, tighter marketing discipline and growing use of direct-to-consumer payments and artificial intelligence across the business. On the company’s earning

VinFast Auto Q1 Earnings Call Highlights

VinFast Auto (NASDAQ:VFS) reported sharply higher first-quarter 2026 vehicle deliveries and revenue, while management said gross margin was pressured by accounting impacts tied to an expanded free-charging program and other adjustments. On the company’s earnings call, Chairman Pham Nhat Quan Anh sa

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

What's Make of Macy's: Berkshire Hathaway's Latest Buy

Berkshire Hathaway just turned over a rock that many would not think to look under. See the status of its latest portfolio addition, retail giant Macy's.

Planet Labs: Coming Back Down to Earth

Planet Labs posted 42% revenue growth and a surging backlog, but after a massive rally investors must weigh execution against valuation

Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secon

Campbell's Q3 Earnings Call Highlights

Campbell's (NASDAQ:CPB) executives used the company’s third-quarter fiscal 2026 earnings question-and-answer session to outline a more cautious operating backdrop heading into fiscal 2027, citing potential incremental inflation tied to higher oil prices, continued pressure in snacks and a focus on b

inkl

Read news from The Economist, FT, and more,
with one subscription

AstroNova Q1 Earnings Call Highlights

AstroNova (NASDAQ:ALOT) reported higher fiscal first-quarter revenue and improved profitability, driven primarily by strength in its Aerospace segment, as management said the company is benefiting from commercial aircraft demand, growing orders and internal cost controls. On the company’s fiscal 20

Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong

Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong

DocuSign's earnings selloff looks harsh. IAM momentum, buybacks and low expectations could make this turnaround worth watching.

Meta Unveils Subscriptions: A New Offering With Real Growth Potential

Meta Unveils Subscriptions: A New Offering With Real Growth Potential

Meta Platforms may be listening to investor complaints on monetization, unveiling several subscription plans to get more out of its huge user base.

BASF Bets on China Growth as Zhanjiang Site Targets €5 Billion in Sales by 2030

Basf (ETR:BAS) executives said the company’s new Zhanjiang Verbund site in Guangdong province has started operations successfully, positioning the German chemicals group for further growth in China while adding a major new production platform built around digitalization, feedstock flexibility and re

3 Longevity ETFs to Buy and Hold (and Hold)

3 Longevity ETFs to Buy and Hold (and Hold)

The size of the longevity industry could roughly triple in the next decade, and these ETFs may help to provide access to a fast-growing space.

The Market May Be Missing What’s Changing at BigBear AI

The Market May Be Missing What’s Changing at BigBear AI

BigBear AI is on track to continue rebounding as its transition to AI powered infrastructure provider to world agencies gains traction.

CME Group CEO Blasts Bitcoin Perpetual Futures, Warns of ‘2007’ Risk

CME Group (NASDAQ:CME) Chairman and CEO Terry Duffy sharply criticized the Commodity Futures Trading Commission’s approval of a Bitcoin perpetual futures contract for Kalshi, saying the product does not fit his view of a futures contract and raises risks for retail investors. Speaking at an investo

Get all your
news in one place.

100's of premium titles.
One news app.

Chime Financial CEO Maps Growth Roadmap, $2.7B Revenue Target at Conference

Chime Financial (NASDAQ:CHYM) founder and CEO Chris Britt outlined the digital banking company’s growth strategy, product roadmap and margin targets during a presentation at the William Blair conference, emphasizing Chime’s focus on primary checking relationships and mainstream U.S. consumers. Brit

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York. Kuan said the company believes the therapy cou

Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference

Certara (NASDAQ:CERT) executives outlined the company’s strategic realignment, artificial intelligence initiatives and cost priorities during a discussion at Jefferies’ 2026 Global Healthcare Conference, with newly appointed Chief Executive Officer Jon Resnick saying the company is focused on creati

These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?

MetLife, Globe Life, and Unum Group are hitting 52-week highs as P&C premiums decline, rewarding insurers with life, group benefits, and health exposure.

Get all your
news in one place.

100's of premium titles.
One news app.

Celsius Plots Energy Drink Comeback as Alani, Rockstar Deals Reshape Growth

Celsius (NASDAQ:CELH) executives said the company is working through a major portfolio transition as it integrates Alani and Rockstar into its platform while repositioning the core Celsius brand for renewed growth. Speaking at an investor conference, Chairman and CEO John Fieldly described the comp

3 Stocks Under $20 to Buy Before a Broader Market Rally

Market rotation into robotics, crypto infrastructure, AI data centers, and precious metals is creating opportunities in speculative stocks under $20, including SERV, BTBT, and CDE.

Petco Faces Tough Competition, But Momentum Is Building

Petco Health and Wellness is becoming a comprehensive petcare services destination capable of competing with Chewy for market share.

The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It

The housing lock-in effect is limiting existing home supply. These three homebuilder stocks could benefit if interest rates move lower

3 ETFs For the Coming Genomics Revolution

Genomics companies are an exciting frontier in health care, and ETFs can help to diversify to control risk while positioning investors to benefit.

The Energy Trade Is Bigger Than Oil Prices: 3 Stocks to Buy and 2 to Sell

U.S. rig counts are climbing for the first time in years. Here are three energy stocks to buy on the dip — and two names analysts say to avoid right now.

CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

1 … 12 13 14 15

People

Pham Nhat Vuong

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Berkshire Hathaway

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

391,042 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play